Wyeth

Pfizer Corporation

University of Pennsylvania

Genetics Institute, Inc.

Xiang-Yang Tan

Lioudmila Tchistiakova

Riyez Karim

Geertruida Machteld Veldman

David S Howland

Margaret Maria Zaleska

Menelas N Pangalos

Seung Poon Kwak

Pamela Kelley

Frank S Walsh

Kimberly Ann Marquette

Samuel Goldman

Debra D Donaldson

Lisa Anne Collins-Racie

Christopher John Corcoran

Edward Roland Lavallie

Angela Widom

Marion T Kasaian

John Adam Nowak

William Kelley, Legal Representative

John L Knopf

Jose William Saldanha

Davinder Gill

Lori J Fitz

Laura Lin

Eric Feyfant

Kevin Delos Parris

Tania Shane

Nancy L Wood

Bruce Jacobson

Macy X Jin

Amy Sze Pui Tam

Debra D Pittman

Jing Li

Lynette A Fouser

Kathleen N Tomkinson

Karen Wallace

Erika L F Holzbaur-Howland

Nicholas Weber

Geertruida M Veldan

Lynette Fouser

Lioudmila Gennadievna Tchistiakova

Erika Lf Holzbaur-Howland

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Antibody to GDF8 and uses thereof

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Method for treating muscle wasting syndrome using antagonist antibodies against GDF-8

The disclosure provides novel molecules related to growth and differentiation factor 8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8 associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Method for treating sarcopenia using antagonist antibodies against GDF-8

Method for treating cachexia using antagonist antibodies against GDF-8

Polynucleotides encoding antagonist antibodies against GDF-8

Method for treating muscular dystrophy using antagonist antibodies against GDF-8

This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.

Antibodies against human interleukin-13 and uses therefor

Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.

Nucleic acids encoding IL-13 binding agents

Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8 associated disorders

Antagonist antibodies against GDF-8

Antibodies and antigen-binding fragments thereof that bind interleukin-22 (IL-22), in particular, human IL-22, and their uses in regulating IL-22-associated immune responses are disclosed. The antibodies disclosed herein are useful in diagnosing, preventing, or treating IL-22-associated immune disorders, e.g., autoimmune disorders (e.g., arthritis).

Monoclonal antibodies against interleukin-22

Antibodies against human interleukin-13 and pharmaceutical compositions thereof

Growing community of inventors

Reading, MA, United States of America

Xiang-Yang Tan